Catheter Precision, Inc. (AMEX: VTAK) Stock Competitors & Peer Comparison
See VTAK's competitors and their performance on the AMEX and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for VTAK and its AMEX peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| VTAK | $0.15 | -0.66% | 317.4K | -0.02 | -$8.78 | N/A |
| ABT | $103.70 | +1.16% | 179.4B | 19.90 | $5.21 | +2.43% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| MDT | $95.41 | -1.22% | 122B | 17.25 | $5.53 | +2.99% |
| SYK | $307.15 | +0.02% | 117.8B | 22.94 | $13.39 | +1.14% |
| BSX | $45.69 | -0.70% | 66.2B | 14.73 | $3.10 | N/A |
| EW | $89.07 | -1.13% | 51.3B | 32.99 | $2.70 | N/A |
| GEHC | $71.45 | +0.10% | 32.3B | 15.67 | $4.56 | +0.20% |
| DXCM | $77.94 | -0.49% | 29.4B | 30.56 | $2.55 | N/A |
| PHG | $26.89 | +2.52% | 25.8B | 15.38 | $1.75 | +3.68% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
VTAK vs ABT Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, ABT has a market cap of 179.4B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while ABT trades at $103.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas ABT's P/E ratio is 19.90. In terms of profitability, VTAK's ROE is -1.24%, compared to ABT's ROE of +0.09%. Regarding short-term risk, VTAK is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
VTAK vs BSX-PA Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, VTAK's ROE is -1.24%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, VTAK is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check BSX-PA's competition here
Medtronic Plc (NYSE: MDT)
VTAK vs MDT Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, MDT has a market cap of 122B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while MDT trades at $95.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas MDT's P/E ratio is 17.25. In terms of profitability, VTAK's ROE is -1.24%, compared to MDT's ROE of +0.11%. Regarding short-term risk, VTAK is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check MDT's competition here
Stryker Corporation (NYSE: SYK)
VTAK vs SYK Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, SYK has a market cap of 117.8B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while SYK trades at $307.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas SYK's P/E ratio is 22.94. In terms of profitability, VTAK's ROE is -1.24%, compared to SYK's ROE of +0.16%. Regarding short-term risk, VTAK is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check SYK's competition here
Boston Scientific Corporation (NYSE: BSX)
VTAK vs BSX Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, BSX has a market cap of 66.2B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while BSX trades at $45.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas BSX's P/E ratio is 14.73. In terms of profitability, VTAK's ROE is -1.24%, compared to BSX's ROE of +0.15%. Regarding short-term risk, VTAK is more volatile compared to BSX. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
VTAK vs EW Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, EW has a market cap of 51.3B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while EW trades at $89.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas EW's P/E ratio is 32.99. In terms of profitability, VTAK's ROE is -1.24%, compared to EW's ROE of +0.10%. Regarding short-term risk, VTAK is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check EW's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
VTAK vs GEHC Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, GEHC has a market cap of 32.3B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while GEHC trades at $71.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas GEHC's P/E ratio is 15.67. In terms of profitability, VTAK's ROE is -1.24%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, VTAK is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check GEHC's competition here
DexCom, Inc. (NASDAQ: DXCM)
VTAK vs DXCM Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, DXCM has a market cap of 29.4B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while DXCM trades at $77.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas DXCM's P/E ratio is 30.56. In terms of profitability, VTAK's ROE is -1.24%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, VTAK is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check DXCM's competition here
Koninklijke Philips N.V. (NYSE: PHG)
VTAK vs PHG Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, PHG has a market cap of 25.8B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while PHG trades at $26.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas PHG's P/E ratio is 15.38. In terms of profitability, VTAK's ROE is -1.24%, compared to PHG's ROE of +0.10%. Regarding short-term risk, VTAK is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
VTAK vs ZBH Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, ZBH has a market cap of 18.8B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while ZBH trades at $98.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas ZBH's P/E ratio is 11.62. In terms of profitability, VTAK's ROE is -1.24%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, VTAK is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
VTAK vs ABMD Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas ABMD's P/E ratio is 65.36. In terms of profitability, VTAK's ROE is -1.24%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, VTAK is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check ABMD's competition here
Smith & Nephew plc (NYSE: SNN)
VTAK vs SNN Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, SNN has a market cap of 12.9B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while SNN trades at $30.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas SNN's P/E ratio is 20.81. In terms of profitability, VTAK's ROE is -1.24%, compared to SNN's ROE of +0.12%. Regarding short-term risk, VTAK is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check SNN's competition here
Penumbra, Inc. (NYSE: PEN)
VTAK vs PEN Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, PEN has a market cap of 12.8B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while PEN trades at $324.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas PEN's P/E ratio is 84.77. In terms of profitability, VTAK's ROE is -1.24%, compared to PEN's ROE of +0.11%. Regarding short-term risk, VTAK is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check PEN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
VTAK vs SWAV Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas SWAV's P/E ratio is 78.76. In terms of profitability, VTAK's ROE is -1.24%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, VTAK is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check SWAV's competition here
Align Technology, Inc. (NASDAQ: ALGN)
VTAK vs ALGN Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, ALGN has a market cap of 11B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while ALGN trades at $154.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas ALGN's P/E ratio is 14.08. In terms of profitability, VTAK's ROE is -1.24%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, VTAK is more volatile compared to ALGN. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check ALGN's competition here
Globus Medical, Inc. (NYSE: GMED)
VTAK vs GMED Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, GMED has a market cap of 10.9B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while GMED trades at $81.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas GMED's P/E ratio is 18.33. In terms of profitability, VTAK's ROE is -1.24%, compared to GMED's ROE of +0.12%. Regarding short-term risk, VTAK is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check GMED's competition here
Glaukos Corporation (NYSE: GKOS)
VTAK vs GKOS Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, GKOS has a market cap of 10.6B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while GKOS trades at $178.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas GKOS's P/E ratio is -208.02. In terms of profitability, VTAK's ROE is -1.24%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, VTAK is more volatile compared to GKOS. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check GKOS's competition here
Insulet Corp. (NASDAQ: PODD)
VTAK vs PODD Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, PODD has a market cap of 10.3B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while PODD trades at $149.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas PODD's P/E ratio is 25.39. In terms of profitability, VTAK's ROE is -1.24%, compared to PODD's ROE of +0.27%. Regarding short-term risk, VTAK is more volatile compared to PODD. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check PODD's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
VTAK vs BIO Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, BIO has a market cap of 9.9B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while BIO trades at $369.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas BIO's P/E ratio is 39.89. In terms of profitability, VTAK's ROE is -1.24%, compared to BIO's ROE of +0.03%. Regarding short-term risk, VTAK is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check BIO's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
VTAK vs BIO-B Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, BIO-B has a market cap of 9.8B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while BIO-B trades at $365.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas BIO-B's P/E ratio is -64.41. In terms of profitability, VTAK's ROE is -1.24%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, VTAK is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check BIO-B's competition here
Masimo Corporation (NASDAQ: MASI)
VTAK vs MASI Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas MASI's P/E ratio is 44.43. In terms of profitability, VTAK's ROE is -1.24%, compared to MASI's ROE of +0.09%. Regarding short-term risk, VTAK is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check MASI's competition here
Bruker Corporation (NASDAQ: BRKRP)
VTAK vs BRKRP Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, BRKRP has a market cap of 8.8B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while BRKRP trades at $421.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas BRKRP's P/E ratio is 230.70. In terms of profitability, VTAK's ROE is -1.24%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, VTAK is more volatile compared to BRKRP. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check BRKRP's competition here
Bruker Corporation (NASDAQ: BRKR)
VTAK vs BRKR Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, BRKR has a market cap of 8.8B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while BRKR trades at $57.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas BRKR's P/E ratio is 28.94. In terms of profitability, VTAK's ROE is -1.24%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, VTAK is more volatile compared to BRKR. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check BRKR's competition here
Haemonetics Corporation (NYSE: HAE)
VTAK vs HAE Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, HAE has a market cap of 5.4B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while HAE trades at $118.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas HAE's P/E ratio is 23.65. In terms of profitability, VTAK's ROE is -1.24%, compared to HAE's ROE of +0.11%. Regarding short-term risk, VTAK is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check HAE's competition here
Inari Medical, Inc. (NASDAQ: NARI)
VTAK vs NARI Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas NARI's P/E ratio is -59.24. In terms of profitability, VTAK's ROE is -1.24%, compared to NARI's ROE of -0.00%. Regarding short-term risk, VTAK is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check NARI's competition here
LivaNova PLC (NASDAQ: LIVN)
VTAK vs LIVN Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, LIVN has a market cap of 4.4B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while LIVN trades at $80.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas LIVN's P/E ratio is 19.22. In terms of profitability, VTAK's ROE is -1.24%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, VTAK is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check LIVN's competition here
Integer Holdings Corporation (NYSE: ITGR)
VTAK vs ITGR Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while ITGR trades at $126.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas ITGR's P/E ratio is 19.93. In terms of profitability, VTAK's ROE is -1.24%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, VTAK is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check ITGR's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
VTAK vs IRTC Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, IRTC has a market cap of 4B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while IRTC trades at $121.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas IRTC's P/E ratio is -282.02. In terms of profitability, VTAK's ROE is -1.24%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, VTAK is more volatile compared to IRTC. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check IRTC's competition here
Neogen Corporation (NASDAQ: NEOG)
VTAK vs NEOG Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, NEOG has a market cap of 2.7B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while NEOG trades at $12.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas NEOG's P/E ratio is 43.54. In terms of profitability, VTAK's ROE is -1.24%, compared to NEOG's ROE of -0.03%. Regarding short-term risk, VTAK is more volatile compared to NEOG. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check NEOG's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
VTAK vs TMDX Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, TMDX has a market cap of 2.5B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while TMDX trades at $70.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas TMDX's P/E ratio is 35.91. In terms of profitability, VTAK's ROE is -1.24%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, VTAK is more volatile compared to TMDX. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check TMDX's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
VTAK vs UFPT Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, UFPT has a market cap of 2.3B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while UFPT trades at $295.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas UFPT's P/E ratio is 30.21. In terms of profitability, VTAK's ROE is -1.24%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, VTAK is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check UFPT's competition here
AxoGen, Inc. (NASDAQ: AXGN)
VTAK vs AXGN Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, AXGN has a market cap of 2.2B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while AXGN trades at $38.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas AXGN's P/E ratio is 100.16. In terms of profitability, VTAK's ROE is -1.24%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, VTAK is more volatile compared to AXGN. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check AXGN's competition here
NuVasive, Inc. (NASDAQ: NUVA)
VTAK vs NUVA Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas NUVA's P/E ratio is 75.00. In terms of profitability, VTAK's ROE is -1.24%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, VTAK is more volatile compared to NUVA. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check NUVA's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
VTAK vs INSP Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, INSP has a market cap of 2.1B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while INSP trades at $71.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas INSP's P/E ratio is 31.32. In terms of profitability, VTAK's ROE is -1.24%, compared to INSP's ROE of +0.18%. Regarding short-term risk, VTAK is more volatile compared to INSP. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check INSP's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
VTAK vs ESTA Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, ESTA has a market cap of 1.9B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while ESTA trades at $63.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas ESTA's P/E ratio is -50.63. In terms of profitability, VTAK's ROE is -1.24%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, VTAK is more volatile compared to ESTA. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check ESTA's competition here
Butterfly Network, Inc. (NYSE: BFLY)
VTAK vs BFLY Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, BFLY has a market cap of 1.8B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while BFLY trades at $6.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas BFLY's P/E ratio is -28.17. In terms of profitability, VTAK's ROE is -1.24%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, VTAK is more volatile compared to BFLY. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check BFLY's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
VTAK vs ATEC Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, ATEC has a market cap of 1.7B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while ATEC trades at $11.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas ATEC's P/E ratio is -185.17. In terms of profitability, VTAK's ROE is -1.24%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, VTAK is more volatile compared to ATEC. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check ATEC's competition here
Novocure Ltd (NASDAQ: NVCR)
VTAK vs NVCR Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, NVCR has a market cap of 1.7B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while NVCR trades at $14.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas NVCR's P/E ratio is -11.29. In terms of profitability, VTAK's ROE is -1.24%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, VTAK is more volatile compared to NVCR. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check NVCR's competition here
CONMED Corporation (NYSE: CNMD)
VTAK vs CNMD Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while CNMD trades at $49.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas CNMD's P/E ratio is 10.80. In terms of profitability, VTAK's ROE is -1.24%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, VTAK is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check CNMD's competition here
Heska Corporation (NASDAQ: HSKA)
VTAK vs HSKA Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas HSKA's P/E ratio is -62.49. In terms of profitability, VTAK's ROE is -1.24%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, VTAK is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check HSKA's competition here
Enovis Corporation (NYSE: ENOV)
VTAK vs ENOV Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, ENOV has a market cap of 1.2B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while ENOV trades at $21.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas ENOV's P/E ratio is 6.04. In terms of profitability, VTAK's ROE is -1.24%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, VTAK is more volatile compared to ENOV. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check ENOV's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
VTAK vs TNDM Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, TNDM has a market cap of 1.2B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while TNDM trades at $17.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas TNDM's P/E ratio is -18.74. In terms of profitability, VTAK's ROE is -1.24%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, VTAK is more volatile compared to TNDM. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check TNDM's competition here
Avanos Medical, Inc. (NYSE: AVNS)
VTAK vs AVNS Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas AVNS's P/E ratio is 27.77. In terms of profitability, VTAK's ROE is -1.24%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, VTAK is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check AVNS's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
VTAK vs PRCT Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, PRCT has a market cap of 1.1B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while PRCT trades at $19.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas PRCT's P/E ratio is -10.29. In terms of profitability, VTAK's ROE is -1.24%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, VTAK is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for VTAK.Check PRCT's competition here
Artivion, Inc. (NYSE: AORT)
VTAK vs AORT Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while AORT trades at $23.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas AORT's P/E ratio is 38.82. In terms of profitability, VTAK's ROE is -1.24%, compared to AORT's ROE of -0.01%. Regarding short-term risk, VTAK is more volatile compared to AORT. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check AORT's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
VTAK vs LMRI Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while LMRI trades at $11.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas LMRI's P/E ratio is -22.69. In terms of profitability, VTAK's ROE is -1.24%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, VTAK is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for VTAK.Check LMRI's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
VTAK vs SILK Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas SILK's P/E ratio is -18.96. In terms of profitability, VTAK's ROE is -1.24%, compared to SILK's ROE of -0.35%. Regarding short-term risk, VTAK is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check SILK's competition here
Paragon 28, Inc. (NYSE: FNA)
VTAK vs FNA Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas FNA's P/E ratio is -19.83. In terms of profitability, VTAK's ROE is -1.24%, compared to FNA's ROE of -0.35%. Regarding short-term risk, VTAK is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check FNA's competition here
IRadimed Corporation (NASDAQ: IRMD)
VTAK vs IRMD Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while IRMD trades at $85.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas IRMD's P/E ratio is 43.13. In terms of profitability, VTAK's ROE is -1.24%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, VTAK is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check IRMD's competition here
CeriBell, Inc. (NASDAQ: CBLL)
VTAK vs CBLL Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, CBLL has a market cap of 1B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while CBLL trades at $27.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas CBLL's P/E ratio is -15.41. In terms of profitability, VTAK's ROE is -1.24%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, VTAK is more volatile compared to CBLL. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check CBLL's competition here
Bioventus Inc. (NASDAQ: BVS)
VTAK vs BVS Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, BVS has a market cap of 1B. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while BVS trades at $14.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas BVS's P/E ratio is 19.68. In terms of profitability, VTAK's ROE is -1.24%, compared to BVS's ROE of +0.28%. Regarding short-term risk, VTAK is more volatile compared to BVS. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check BVS's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
VTAK vs SIBN Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, SIBN has a market cap of 962.7M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while SIBN trades at $21.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas SIBN's P/E ratio is -63.18. In terms of profitability, VTAK's ROE is -1.24%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, VTAK is more volatile compared to SIBN. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check SIBN's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
VTAK vs IART Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, IART has a market cap of 926.3M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while IART trades at $11.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas IART's P/E ratio is 5.05. In terms of profitability, VTAK's ROE is -1.24%, compared to IART's ROE of +0.02%. Regarding short-term risk, VTAK is more volatile compared to IART. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check IART's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
VTAK vs BBNX Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, BBNX has a market cap of 862M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while BBNX trades at $19.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas BBNX's P/E ratio is -11.61. In terms of profitability, VTAK's ROE is -1.24%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, VTAK is more volatile compared to BBNX. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check BBNX's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
VTAK vs CSII Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, CSII has a market cap of 844M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas CSII's P/E ratio is -20.83. In terms of profitability, VTAK's ROE is -1.24%, compared to CSII's ROE of -0.14%. Regarding short-term risk, VTAK is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check CSII's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
VTAK vs AHCO Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, AHCO has a market cap of 820.8M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while AHCO trades at $6.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas AHCO's P/E ratio is 12.29. In terms of profitability, VTAK's ROE is -1.24%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, VTAK is more volatile compared to AHCO. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check AHCO's competition here
InMode Ltd. (NASDAQ: INMD)
VTAK vs INMD Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, INMD has a market cap of 803.9M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while INMD trades at $13.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas INMD's P/E ratio is 9.70. In terms of profitability, VTAK's ROE is -1.24%, compared to INMD's ROE of +0.12%. Regarding short-term risk, VTAK is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check INMD's competition here
Varex Imaging Corporation (NASDAQ: VREX)
VTAK vs VREX Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, VREX has a market cap of 782.2M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while VREX trades at $18.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas VREX's P/E ratio is 19.39. In terms of profitability, VTAK's ROE is -1.24%, compared to VREX's ROE of +0.05%. Regarding short-term risk, VTAK is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check VREX's competition here
Picard Medical, Inc. (AMEX: PMI)
VTAK vs PMI Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, PMI has a market cap of 758.9M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while PMI trades at $7.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas PMI's P/E ratio is -6.16. In terms of profitability, VTAK's ROE is -1.24%, compared to PMI's ROE of -9.31%. Regarding short-term risk, VTAK is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for VTAK.Check PMI's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
VTAK vs CTKB Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, CTKB has a market cap of 726.6M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while CTKB trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas CTKB's P/E ratio is -29.61. In terms of profitability, VTAK's ROE is -1.24%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, VTAK is more volatile compared to CTKB. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check CTKB's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
VTAK vs PACB Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, PACB has a market cap of 655.9M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while PACB trades at $2.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas PACB's P/E ratio is -5.15. In terms of profitability, VTAK's ROE is -1.24%, compared to PACB's ROE of -49.62%. Regarding short-term risk, VTAK is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for VTAK.Check PACB's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
VTAK vs KIDS Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, KIDS has a market cap of 638.9M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while KIDS trades at $24.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas KIDS's P/E ratio is -20.74. In terms of profitability, VTAK's ROE is -1.24%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, VTAK is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check KIDS's competition here
Surmodics, Inc. (NASDAQ: SRDX)
VTAK vs SRDX Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas SRDX's P/E ratio is -34.66. In terms of profitability, VTAK's ROE is -1.24%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, VTAK is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check SRDX's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
VTAK vs APEN Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas APEN's P/E ratio is -9.43. In terms of profitability, VTAK's ROE is -1.24%, compared to APEN's ROE of -0.85%. Regarding short-term risk, VTAK is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check APEN's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
VTAK vs AVR Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, AVR has a market cap of 571.6M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while AVR trades at $5.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas AVR's P/E ratio is -3.02. In terms of profitability, VTAK's ROE is -1.24%, compared to AVR's ROE of -0.78%. Regarding short-term risk, VTAK is more volatile compared to AVR. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check AVR's competition here
ZimVie Inc. (NASDAQ: ZIMV)
VTAK vs ZIMV Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, VTAK's ROE is -1.24%, compared to ZIMV's ROE of -0.07%. Regarding short-term risk, VTAK is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check ZIMV's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
VTAK vs TCMD Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, TCMD has a market cap of 535.5M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while TCMD trades at $23.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas TCMD's P/E ratio is 21.89. In terms of profitability, VTAK's ROE is -1.24%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, VTAK is more volatile compared to TCMD. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check TCMD's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
VTAK vs DCTH Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, DCTH has a market cap of 500.4M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while DCTH trades at $14.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas DCTH's P/E ratio is 1442.00. In terms of profitability, VTAK's ROE is -1.24%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, VTAK is more volatile compared to DCTH. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check DCTH's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
VTAK vs SGHT Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, SGHT has a market cap of 495.2M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while SGHT trades at $8.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas SGHT's P/E ratio is -16.05. In terms of profitability, VTAK's ROE is -1.24%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, VTAK is more volatile compared to SGHT. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check SGHT's competition here
Cerus Corporation (NASDAQ: CERS)
VTAK vs CERS Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, CERS has a market cap of 469.6M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while CERS trades at $2.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas CERS's P/E ratio is -77.41. In terms of profitability, VTAK's ROE is -1.24%, compared to CERS's ROE of -0.10%. Regarding short-term risk, VTAK is more volatile compared to CERS. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check CERS's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
VTAK vs SSII Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, SSII has a market cap of 457.1M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while SSII trades at $2.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas SSII's P/E ratio is -38.00. In terms of profitability, VTAK's ROE is -1.24%, compared to SSII's ROE of -0.27%. Regarding short-term risk, VTAK is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for VTAK.Check SSII's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
VTAK vs NPCE Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, NPCE has a market cap of 443.1M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while NPCE trades at $12.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas NPCE's P/E ratio is -22.65. In terms of profitability, VTAK's ROE is -1.24%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, VTAK is more volatile compared to NPCE. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check NPCE's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
VTAK vs SENS Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, SENS has a market cap of 397.1M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while SENS trades at $7.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas SENS's P/E ratio is -3.37. In terms of profitability, VTAK's ROE is -1.24%, compared to SENS's ROE of -1.66%. Regarding short-term risk, VTAK is more volatile compared to SENS. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check SENS's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
VTAK vs OFIX Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, OFIX has a market cap of 396.5M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while OFIX trades at $9.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas OFIX's P/E ratio is -6.39. In terms of profitability, VTAK's ROE is -1.24%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, VTAK is more volatile compared to OFIX. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check OFIX's competition here
Avita Medical Inc. (NASDAQ: RCEL)
VTAK vs RCEL Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, RCEL has a market cap of 385.3M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while RCEL trades at $15.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas RCEL's P/E ratio is -10.77. In terms of profitability, VTAK's ROE is -1.24%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, VTAK is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for VTAK.Check RCEL's competition here
CapsoVision, Inc. (NASDAQ: CV)
VTAK vs CV Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, CV has a market cap of 371.9M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while CV trades at $6.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas CV's P/E ratio is -11.10. In terms of profitability, VTAK's ROE is -1.24%, compared to CV's ROE of -1.78%. Regarding short-term risk, VTAK is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for VTAK.Check CV's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
VTAK vs SMLR Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas SMLR's P/E ratio is 3.92. In terms of profitability, VTAK's ROE is -1.24%, compared to SMLR's ROE of +0.20%. Regarding short-term risk, VTAK is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check SMLR's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
VTAK vs CLPT Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, CLPT has a market cap of 278.8M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while CLPT trades at $9.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas CLPT's P/E ratio is -7.75. In terms of profitability, VTAK's ROE is -1.24%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, VTAK is more volatile compared to CLPT. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check CLPT's competition here
Quantum-Si incorporated (NASDAQ: QSI)
VTAK vs QSI Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, QSI has a market cap of 278.5M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while QSI trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas QSI's P/E ratio is -3.04. In terms of profitability, VTAK's ROE is -1.24%, compared to QSI's ROE of -0.47%. Regarding short-term risk, VTAK is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for VTAK.Check QSI's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
VTAK vs TMCI Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, TMCI has a market cap of 277.7M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while TMCI trades at $4.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas TMCI's P/E ratio is -4.54. In terms of profitability, VTAK's ROE is -1.24%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, VTAK is more volatile compared to TMCI. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check TMCI's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
VTAK vs INFU Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, INFU has a market cap of 277.4M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while INFU trades at $13.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas INFU's P/E ratio is 33.98. In terms of profitability, VTAK's ROE is -1.24%, compared to INFU's ROE of +0.15%. Regarding short-term risk, VTAK is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check INFU's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
VTAK vs MGRM Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas MGRM's P/E ratio is -12.00. In terms of profitability, VTAK's ROE is -1.24%, compared to MGRM's ROE of -1.17%. Regarding short-term risk, VTAK is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check MGRM's competition here
Nevro Corp. (NYSE: NVRO)
VTAK vs NVRO Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas NVRO's P/E ratio is -1.91. In terms of profitability, VTAK's ROE is -1.24%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, VTAK is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check NVRO's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
VTAK vs TLSI Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, TLSI has a market cap of 221.1M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while TLSI trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas TLSI's P/E ratio is -2.14. In terms of profitability, VTAK's ROE is -1.24%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, VTAK is more volatile compared to TLSI. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check TLSI's competition here
Electromed, Inc. (AMEX: ELMD)
VTAK vs ELMD Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, ELMD has a market cap of 218.3M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while ELMD trades at $26.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas ELMD's P/E ratio is 20.11. In terms of profitability, VTAK's ROE is -1.24%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, VTAK is more volatile compared to ELMD. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check ELMD's competition here
Profound Medical Corp. (NASDAQ: PROF)
VTAK vs PROF Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, PROF has a market cap of 210.8M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while PROF trades at $5.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas PROF's P/E ratio is -5.89. In terms of profitability, VTAK's ROE is -1.24%, compared to PROF's ROE of -0.56%. Regarding short-term risk, VTAK is more volatile compared to PROF. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check PROF's competition here
RxSight, Inc. (NASDAQ: RXST)
VTAK vs RXST Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, RXST has a market cap of 208.8M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while RXST trades at $5.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas RXST's P/E ratio is -4.44. In terms of profitability, VTAK's ROE is -1.24%, compared to RXST's ROE of -0.17%. Regarding short-term risk, VTAK is more volatile compared to RXST. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check RXST's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
VTAK vs BSGM Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas BSGM's P/E ratio is -5.81. In terms of profitability, VTAK's ROE is -1.24%, compared to BSGM's ROE of +6.96%. Regarding short-term risk, VTAK is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for VTAK.Check BSGM's competition here
Inogen, Inc. (NASDAQ: INGN)
VTAK vs INGN Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, INGN has a market cap of 188.4M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while INGN trades at $7.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas INGN's P/E ratio is -7.80. In terms of profitability, VTAK's ROE is -1.24%, compared to INGN's ROE of -0.13%. Regarding short-term risk, VTAK is more volatile compared to INGN. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check INGN's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
VTAK vs CATX Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, CATX has a market cap of 182.6M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while CATX trades at $1.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas CATX's P/E ratio is -1.20. In terms of profitability, VTAK's ROE is -1.24%, compared to CATX's ROE of -0.42%. Regarding short-term risk, VTAK is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for VTAK.Check CATX's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
VTAK vs MDGS Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas MDGS's P/E ratio is -0.27. In terms of profitability, VTAK's ROE is -1.24%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, VTAK is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for VTAK.Check MDGS's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
VTAK vs QIPT Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas QIPT's P/E ratio is -15.87. In terms of profitability, VTAK's ROE is -1.24%, compared to QIPT's ROE of -0.08%. Regarding short-term risk, VTAK is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check QIPT's competition here
Neuronetics, Inc. (NASDAQ: STIM)
VTAK vs STIM Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, STIM has a market cap of 160.8M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while STIM trades at $2.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas STIM's P/E ratio is -4.80. In terms of profitability, VTAK's ROE is -1.24%, compared to STIM's ROE of -1.51%. Regarding short-term risk, VTAK is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for VTAK.Check STIM's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
VTAK vs FOCL Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, FOCL has a market cap of 156.3M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while FOCL trades at $4.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas FOCL's P/E ratio is -4.03. In terms of profitability, VTAK's ROE is -1.24%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, VTAK is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for VTAK.Check FOCL's competition here
Quanterix Corporation (NASDAQ: QTRX)
VTAK vs QTRX Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, QTRX has a market cap of 135.3M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while QTRX trades at $2.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas QTRX's P/E ratio is -1.13. In terms of profitability, VTAK's ROE is -1.24%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, VTAK is more volatile compared to QTRX. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check QTRX's competition here
Owlet, Inc. (NYSE: OWLT)
VTAK vs OWLT Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, OWLT has a market cap of 120.4M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while OWLT trades at $4.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas OWLT's P/E ratio is -29.43. In terms of profitability, VTAK's ROE is -1.24%, compared to OWLT's ROE of -0.50%. Regarding short-term risk, VTAK is more volatile compared to OWLT. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check OWLT's competition here
iCAD, Inc. (NASDAQ: ICAD)
VTAK vs ICAD Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas ICAD's P/E ratio is -20.37. In terms of profitability, VTAK's ROE is -1.24%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, VTAK is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check ICAD's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
VTAK vs HJLI Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas HJLI's P/E ratio is N/A. In terms of profitability, VTAK's ROE is -1.24%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, VTAK is more volatile compared to HJLI. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check HJLI's competition here
Asensus Surgical, Inc. (AMEX: ASXC)
VTAK vs ASXC Comparison October 2026
Catheter Precision, Inc. (AMEX: VTAK) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VTAK stands at 317.4K. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, VTAK is priced at $0.15 on the AMEX, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VTAK currently has a P/E ratio of -0.02, whereas ASXC's P/E ratio is -1.12. In terms of profitability, VTAK's ROE is -1.24%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, VTAK is more volatile compared to ASXC. This indicates higher risk in terms of short-term price fluctuations for VTAK.Check ASXC's competition here